Revvity Inc (STU:PKN)
€ 112.65 4.2 (3.87%) Market Cap: 13.59 Bil Enterprise Value: 15.56 Bil PE Ratio: 57.01 PB Ratio: 1.82 GF Score: 80/100

PerkinElmer Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 05:30PM GMT
Release Date Price: €145.9 (-3.95%)
Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everybody. I'm Luke Sergott. I cover life sciences tools and diagnostics at Barclays. It's my pleasure to have Prahlad Singh from PerkinElmer. And with that, if you want to make a couple of comments, and then we can just dig into some questions, if you'd like.

Prahlad R. Singh
PerkinElmer, Inc. - CEO, President & Director

Sure, Luke. Thank you. It's great to see everyone. It's good to meet in person. I think sort of to kick it off, Luke, maybe just talk about the company a little bit.

As you see the process of transformation that we have gone through over the past 5 years, we feel really good about where we are, obviously, covered over the last 24 months has been a major driver and a major factor in the company, but it has also given us the opportunity to continue to transform our portfolio. And where we stand today, 80% of PerkinElmer is in Life Sciences and Diagnostics.

And 3/4 of our revenue comes from consumables, reagents, assays, software

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot